Streetbeat News

PIII

P3 Health Partners Inc.

Industry

Medical - Care Facilities

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

Open

0.19

Mkt cap

70M

Volume

234K

High

0.20

P/E Ratio

-0.23

52-wk high

1.78

Low

0.19

Div yield

N/A

52-wk low

0.18

P3 Health Partners Inc. (NASDAQ:PIII) held its Q3 2024 earnings call on November 12, 2024. Key participants included CEO Aric Coffman, CFO Leif Pedersen, and CMO Amir Bacchus. Analysts from Lake Street Capital Markets, Nephron Research, BTIG, and William Blair participated in the call.

Portfolio Pulse from

November 13, 2024 | 2:15 am

P3 Health Partners Inc. (PIII) reported a larger-than-expected loss for Q3, with a loss of $0.31 per share compared to the Zacks Consensus Estimate of a $0.03 loss. This is a significant increase from the $0.12 loss per share reported a year ago.

Portfolio Pulse from

November 13, 2024 | 12:30 am

In Friday's after-market session, several healthcare stocks experienced significant price movements. Healthcare Triangle, Mira Pharmaceuticals, MEI Pharma, TuHURA Biosciences, P3 Health Partners, and OKYO Pharma saw notable gains, while Aclaris Therapeutics, Beyond Air, Qualigen Therapeutics, Nuwellis, Compass Pathways, and Helius Medical Tech experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 8:31 pm

On Thursday, several health care stocks experienced significant intraday movements. Notable gainers included Tevogen Bio Holdings, Molecular Templates, and Kazia Therapeutics, while Biodexa Pharmaceuticals and 180 Life Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 4:31 pm

Insider buying activity has been observed in three penny stocks: P3 Health Partners, XWELL, and ThredUp. This insider activity may indicate confidence in these companies despite recent challenges, such as downbeat earnings for P3 Health Partners and ThredUp's disappointing financial results.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 11:41 am

Insider transactions in penny stocks PodcastOne, P3 Health Partners, and Brightcove indicate potential confidence in these companies. Notable purchases include PodcastOne's director buying 10,000 shares, P3 Health Partners' 10% owner acquiring 90,000 shares, and Brightcove's 10% owner purchasing 16,830 shares.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 12:06 pm

P3 Health Partners has projected its FY24 total revenues to be between $1.45 billion and $1.55 billion, compared to the estimated $1.53 billion.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:56 pm

P3 Health Partners (NASDAQ:PIII) reported Q2 EPS of $(0.15), missing the $(0.05) estimate by 200%. Sales were $379.16M, missing the $383.47M estimate by 1.12%. EPS decreased by 66.67% YoY, while sales increased by 15.22% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:48 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include OneMedNet, Renovaro, Altamira Therapeutics, Purple Biotech, P3 Health Partners, and Qilian Intl Hldg Gr. On the losing side, SILO Pharma, Cue Health, Protagenic Therapeutics, Cytokinetics, SAB Biotherapeutics, and DermTech experienced declines.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 4:31 pm

P3 Health Partners Inc. (NASDAQ:PIII) has announced a private placement of approximately $42.2 million with institutional investors, including affiliates of Chicago Pacific Founders. The funds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.